metricas
covid
Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis Abnormalities of triglyceride rich lipoproteins (TRLs) in type 2 diabetes and in...
Información de la revista
Vol. 22. Núm. S2.
16.º Simposio Científico Alimentación, Lípidos y Aterosclerosis
Páginas 36-38 (diciembre 2010)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 22. Núm. S2.
16.º Simposio Científico Alimentación, Lípidos y Aterosclerosis
Páginas 36-38 (diciembre 2010)
Acceso a texto completo
Abnormalities of triglyceride rich lipoproteins (TRLs) in type 2 diabetes and insulin resistance
Visitas
931
Marja-Riitta Taskinen
Division of Cardiology, Department of Medicine, Institute of Clinical Medicine, University of Helsinki, Finland
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
References
[1.]
N. Matikainen.
Taskinen M-R. Postprandial triglyceride-rich lipoproteins in insulin resistance and Type 2 diabetes.
Future Lipidol, 35 (2008), pp. 531-543
[2.]
B.G. Nordestgaard, M. Benn, P. Schnohr, A. Tybjaerg-Hansen.
Non-fasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.
JAMA, 298 (2007), pp. 299-308
[3.]
S. Bansal, J.E. Buring, N. Rifai, S. Mora, F.M. Sacks, P.M. Ridker.
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.
JAMA, 298 (2007), pp. 309-316
[4.]
K. Adeli, G.F. Lewis.
Intestinal lipoprotein overproduction in insulin-resistant states.
Curr Opin Lipidol, 19 (2008), pp. 221-228
[5.]
A. Hiukka, J. Fruchart-Najib, E. Leinonen, H. Hilden, J.C. Fruchart, M.R. Taskinen.
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.
Diabetologia, 48 (2005), pp. 1207-1215
[6.]
M. Adiels, S.O. Olofsson, M.R. Taskinen, J. Borén.
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Arterioscler Thromb Vasc Biol, 28 (2008), pp. 1225-1236
[7.]
N. Stefan, K. Kantartzis, H.U. Häring.
Causes and metabolic consequences of Fatty liver.
Endocr Rev, 29 (2008), pp. 939-960
[8.]
M. Adiels, J. Westerbacka, A. Soro-Paavonen, A.M. Häkkinen, S. Veh-kavaara, M.J. Caslake, et al.
Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance.
Diabetologia, 50 (2007), pp. 2356-2365
[9.]
C. Postic, J. Girard.
Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.
J Clin Invest, 118 (2008), pp. 829-838
[10.]
K.L. Stanhope, J.M. Schwarz, N.L. Keim, S.C. Griffen, A.A. Bremer, J.L. Graham, et al.
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans.
J Clin Invest, 119 (2009), pp. 1322-1334
[11.]
K.L. Teff, J. Grudziak, R.R. Townsend, T.N. Dunn, R.W. Grant, S.H. Adams, et al.
Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: influence of insulin resistance on plasma triglyceride responses.
J Clin Endocrinol Metab, 94 (2009), pp. 1562-1569
[12.]
K.J. Williams.
Molecular processes that handle - and mishandle - dietary lipids.
J Clin Invest, 118 (2008), pp. 3247-3259
[13.]
J. Szendroedi, M. Roden.
Ectobic lipids and organ function.
Curr Opin Lipidol, 20 (2009), pp. 50-56
Copyright © 2010. Sociedad Española de Arteriosclerosis y Elsevier España S.L.
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.arteri.2020.09.003
No mostrar más